122 related articles for article (PubMed ID: 27051921)
1. [EXPERIENCE IN USE OF HEPATOPROTECTOR REMAXOL FOR TREATING LIVER CIRRHOSIS].
Gridchik IE; Kurdyakov AV; Matveev AI
Eksp Klin Farmakol; 2015; 78(12):11-4. PubMed ID: 27051921
[TBL] [Abstract][Full Text] [Related]
2. [Possibilities of remaxol in prevention of toxic hepatitis during chemotherapy for cancer patients].
Cherenkov VG; Petrov AB; Vasil'eva TM; Strozhenkov MM
Vopr Onkol; 2013; 59(3):369-74. PubMed ID: 23909040
[TBL] [Abstract][Full Text] [Related]
3. [Effectiveness of the hepatoprotective activity of reamberine, remaxol, and ademethionine and risk assessment in their use in patients with respiratory tuberculosis and drug-induced liver injury].
Sukhanov DS
Ter Arkh; 2012; 84(11):26-9. PubMed ID: 23252243
[TBL] [Abstract][Full Text] [Related]
4. [Comparative effectiveness hepatotropic activity remaxol and Essentiale N in chronic viral hepatitis].
Pavelkina VF; Ampleeva NP
Eksp Klin Farmakol; 2014; 77(12):17-21. PubMed ID: 25739188
[TBL] [Abstract][Full Text] [Related]
5. Orthotopic liver transplantation in critically ill cirrhotic patients with multi-organ failure: a single-center experience.
Umgelter A; Lange K; Kornberg A; Büchler P; Friess H; Schmid RM
Transplant Proc; 2011 Dec; 43(10):3762-8. PubMed ID: 22172843
[TBL] [Abstract][Full Text] [Related]
6. [The efficacy of remaxol addition in the treatment of alcohol withdrawal syndrome].
Vinnikova MA; Utkin SI; Nenasteva AY; Zakharov MV
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(1):40-46. PubMed ID: 26977624
[TBL] [Abstract][Full Text] [Related]
7. [Metaanalytic Approach to Evaluate Clinical Effectiveness of Infusion Succinnate-Containing Remaxol in Liver Pathologies of Diverse Genesis].
Mazina NK; Mazin PV
Antibiot Khimioter; 2015; 60(11-12):43-9. PubMed ID: 27141647
[TBL] [Abstract][Full Text] [Related]
8. Multiple organ system failure in critically ill cirrhotic patients. A comparison of two multiple organ dysfunction/failure scoring systems.
Tsai MH; Peng YS; Lien JM; Weng HH; Ho YP; Yang C; Chu YY; Chen YC; Fang JT; Chiu CT; Chen PC
Digestion; 2004; 69(3):190-200. PubMed ID: 15178929
[TBL] [Abstract][Full Text] [Related]
9. The outcome of critical illness in decompensated alcoholic liver cirrhosis.
Kavli M; Strøm T; Carlsson M; Dahler-Eriksen B; Toft P
Acta Anaesthesiol Scand; 2012 Sep; 56(8):987-94. PubMed ID: 22471740
[TBL] [Abstract][Full Text] [Related]
10. Combination of granulocyte colony-stimulating factor and erythropoietin improves outcomes of patients with decompensated cirrhosis.
Kedarisetty CK; Anand L; Bhardwaj A; Bhadoria AS; Kumar G; Vyas AK; David P; Trehanpati N; Rastogi A; Bihari C; Maiwall R; Garg HK; Vashishtha C; Kumar M; Bhatia V; Sarin SK
Gastroenterology; 2015 Jun; 148(7):1362-70.e7. PubMed ID: 25749502
[TBL] [Abstract][Full Text] [Related]
11. [PLACE REMAXOL AS A HEPATOPROTECTOR IN INTENSIVE THERAPY OF PERVASIVE PERITONITIS].
Orlov YP; Lukach VN; Govorova NV; Gluschenko AV; Dmitriva OD
Anesteziol Reanimatol; 2015; 60(6):24-9. PubMed ID: 27025129
[TBL] [Abstract][Full Text] [Related]
12. [Effect of hepatoprotector remaxol infusion on liver function in obstructive jaundice model in rats].
Smirnova NG; Chefu SG; Kovalenko AL; Vlasov TD
Eksp Klin Farmakol; 2010 Sep; 73(9):24-7. PubMed ID: 21086649
[TBL] [Abstract][Full Text] [Related]
13. [IMPROVING THE EFFICACY OF THERAPY FOR PATIENTS WITH MYOCARDIAL INFARCTION COMPLICATED BY CIRCULATORY FAILURE].
Zhenilo VM; Avsaragova AZ; Astakhova ZT
Eksp Klin Farmakol; 2016; 79(3):13-7. PubMed ID: 27455573
[TBL] [Abstract][Full Text] [Related]
14. [The efficacy of remaxol in patients with liver cirrhosis].
Zarivchatskiĭ MF; Kamenskikh ED; Mugatarov IN
Khirurgiia (Mosk); 2013; (3):79-82. PubMed ID: 23612344
[No Abstract] [Full Text] [Related]
15. Outcome of patients with cirrhosis requiring mechanical ventilation in ICU.
Levesque E; Saliba F; Ichaï P; Samuel D
J Hepatol; 2014 Mar; 60(3):570-8. PubMed ID: 24280294
[TBL] [Abstract][Full Text] [Related]
16. Role of serum creatinine and prognostic scoring systems in assessing hospital mortality in critically ill cirrhotic patients with upper gastrointestinal bleeding.
Chen YC; Tsai MH; Hsu CW; Ho YP; Lien JM; Chang MY; Fang JT; Huang CC; Chen PC
J Nephrol; 2003; 16(4):558-65. PubMed ID: 14696759
[TBL] [Abstract][Full Text] [Related]
17. Outcome scoring systems for short-term prognosis in critically ill cirrhotic patients.
Tu KH; Jenq CC; Tsai MH; Hsu HH; Chang MY; Tian YC; Hung CC; Fang JT; Yang CW; Chen YC
Shock; 2011 Nov; 36(5):445-50. PubMed ID: 21841535
[TBL] [Abstract][Full Text] [Related]
18. [Use of remaxol in the combination therapy of post-withdrawal disorders in alcoholic patients with comorbid liver damage].
Bokhan NA; Abolonin AF; Ankudinova IÉ; Kurgak DI; Mandel' AI
Ter Arkh; 2012; 84(10):51-5. PubMed ID: 23227501
[TBL] [Abstract][Full Text] [Related]
19. Risk factors, sequential organ failure assessment and model for end-stage liver disease scores for predicting short term mortality in cirrhotic patients admitted to intensive care unit.
Cholongitas E; Senzolo M; Patch D; Kwong K; Nikolopoulou V; Leandro G; Shaw S; Burroughs AK
Aliment Pharmacol Ther; 2006 Apr; 23(7):883-93. PubMed ID: 16573791
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacoeconomic Analysis of the Use of Hepatoprotectors in Management of Drug-Associated Liver Injury Due to Hodgkin's Lymphoma Chemotherapy].
Morikov DD; Morikova EG; Dvornichenko VV
Antibiot Khimioter; 2015; 60(7-8):23-6. PubMed ID: 26863739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
